Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 10,388

Document Document Title
WO/2023/233820A1
[Problem] The purpose of the present invention is to provide an agent for promoting a decrease in MDA concentration, an agent for promoting a decrease in 8-OHdG concentration, an agent for promoting an increase in ZIP4 concentration, or ...  
WO/2023/234809A1
The invention relates to a method for preventing iodine radionuclide damage to the human or animal body. A bound form of 4-hydroxy 3,5-diiodophenyl-containing compounds, for example within protein or peptide molecules, is introduced oral...  
WO/2023/226315A1
Provided is an anti-fatigue traditional Chinese medicine compound composition, composed of, in parts by weight, 9-15 parts of ginseng, 40-50 parts of rhizoma polygonati, 19-25 parts of Astragalus membranaceus, 8-10 parts of white hyacint...  
WO/2023/227054A1
The present invention provides a compound and use thereof, particularly a JWA gene agonist and use thereof in preventing or treating radiation damage. The compound, by means of activating JWA gene expression, enhances the DNA repair capa...  
WO/2023/230307A1
Methods of synthesis of cobinamide compounds with improved yield and purity. Methods and compositions for treating cyanide, sulfide, sodium azide, or methane-thiol exposure in a subject.  
WO/2023/229438A1
The present invention relates to a microfluidic reactor for producing microcapsules and external stimuli-responsive microcapsules produced by using same and, more specifically, to: a microfluidic reactor capable of effectively producing ...  
WO/2023/226171A1
A cod skin collagen peptide-loaded trimethyl chitosan nanoparticle and the use thereof. A method for preparing the cod skin collagen peptide-loaded trimethyl chitosan nanoparticle, wherein the method comprises: adding an aqueous solution...  
WO/2023/228994A1
The present disclosure addresses the problem of providing at least a technology for enhancing the expression of SIRT3 genes. Said problem is solved by a composition for enhancing SIRT3 gene expression, the composition containing urolithi...  
WO/2023/221977A1
Disclosed in the present invention are a chondroitin sulfate biological polyamine compound, a preparation method therefor and use thereof. The present invention provides a chondroitin sulfate biological polyamine compound, which is a com...  
WO/2023/223223A1
The present invention relates to a pharmaceutical composition for use in preventing and/or reducing hepatotoxicity induced by acetaminophen. Said pharmaceutical composition comprises a combination of acetaminophen and nefopam, as nefopam...  
WO/2023/221338A1
The present application belongs to the technical field of medicine. Provided are a high-stability heavy metal removing composition, use and a dosage form thereof, and a method for preparing same. The composition comprises: A) 70 wt% to 9...  
WO/2023/216952A1
Provided is an anti-ageing use of a uridylic acid, adenylic acid, and yeast peptide composition, relating to the technical field of medicine and healthcare. The composition comprises 5'-uridylic acid, 5'-adenylic acid, and yeast peptide,...  
WO/2023/217405A1
The present invention relates to photostabilized compositions comprising a water-soluble tyrosine- containing compound with a molecular weight of below 1kDa and at least one photosensitive component and a method for stabilizing photosens...  
WO/2023/217179A1
Provided is use of mannose in inhibiting pyroptosis or relieving toxic and side effects of a chemotherapy drug, which relates to the field of medical science and technologies. Mannose inhibits pyroptosis induced by a chemotherapy drug, s...  
WO/2023/216951A1
The present invention relates to an anti-aging composition containing uridine acid, adenylic acid and yeast peptide and use thereof, and belongs to the technical field of medicine health care. The composition is prepared by blending 5'-u...  
WO/2023/217192A1
The present invention provides preparation of a chimeric antigen receptor immune cell constructed based on an MSLN precursor protein and use thereof. Specifically, the present invention provides a chimeric antigen receptor (CAR) modified...  
WO/2023/214201A1
The method of obtaining stable suspensions of heterocrystals of titanium dioxide and particles of silicon dioxide and stable suspensions. Starting material is mixed with an aqueous solution of pharmaceutically acceptable acid, with subse...  
WO/2023/213902A1
The invention relates to remofuscin for use against aging, lysomal dysfunction, for use in stimulating the expression of lysosomal lipase genes and/or lysosomal lipid chaperone genes, and for use in increasing the expression levels of th...  
WO/2023/207054A1
Use of ganoderma lucidum spore oil in preparing a drug for prolonging the survival time of tumor patients. The ganoderma lucidum spore oil has the effect of prolonging the survival time of tumor-bearing mice and is used for preparing the...  
WO/2023/209548A1
The invention relates to flower extracts from L. leonurus var. albiflora white flower, for use in methods of treating or preventing cellular damage of healthy cells caused by a cancer therapy, comprising administering crude or purified e...  
WO/2023/209458A1
The present invention relates to a process for preparation of compositions comprising human umbilical cord blood plasma and a designed specific culture medium to grow these cells in specific conditions. The compositions of the present in...  
WO/2023/206055A1
Provided are a modification and the use of silk fibroin. Calcium in silk fibroin or fibroin fibers is partially or completely removed, so as to obtain the modified silk fibroin with a broad-spectrum antioxidant effect. A method for prepa...  
WO/2023/210740A1
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...  
WO/2023/209212A1
In the field of recombinant antivenoms, a major hurdle to the development of antigen-binding proteins enabling sufficient toxin neutralization is the identification of antigen-binding proteins with both high affinity and broad cross-reac...  
WO/2023/203791A1
One purpose of the present disclosure is to provide a novel pharmaceutical composition, preferably a pharmaceutical composition capable of adsorbing a variety of disease-causing substances in vivo. A pharmaceutical composition that com...  
WO/2023/204279A1
One of the objectives of the present disclosure is to provide a novel adsorbent material to be used for adsorbing a wider range of adsorbates in comparison with non-patent document 1. Another objective of the present disclosure is to pro...  
WO/2023/204278A1
One purpose of the present disclosure is to provide a novel pharmaceutical composition, and preferably, to provide a pharmaceutical composition which makes it possible to adsorb various disease-causing substances inside an organism. A ...  
WO/2023/199241A1
It is an object of the present invention a composition comprising lipoic acid, or a pharmaceutically or food grade acceptable salt thereof or a derivative thereof, and a vitamin D, preferably vitamin D3 and/or vitamin D2, and glutathione...  
WO/2023/199908A1
The present disclosure addresses the problem of providing at least a technique for producing a composition in which urolithins are solubilized. The problem is solved by a method for producing an emulsified composition, the method compris...  
WO/2023/197437A1
The present invention belongs to the field of biological medicines, and particularly relates to a chimeric receptor for improving the killing activity of immune cells and an application thereof. Specifically, the present invention provid...  
WO/2023/199244A1
It is an object of the present invention a composition comprising N-acetylcysteine, or a pharmaceutically or food grade acceptable salt thereof or a derivative thereof, and a vitamin D, preferably vitamin D3 and/or vitamin D2, and prefer...  
WO/2023/193389A1
Provided is a resveratrol-lecithin nanoparticle comprising resveratrol and lecithin encapsulating and/or conjugated to resveratrol. The resveratrol-lecithin nanoparticle features safety and sustained release, and can improve the in-vivo ...  
WO/2023/191310A1
The present invention relates to a composition for improving antioxidant, anti-aging, antibacterial, anti-inflammatory, or cognitive function. More specifically, the composition comprises a solid-phase fermented Schizandra chinensis Bail...  
WO/2023/188931A1
One composite composition according to the present invention contains silicon fine particles having an average particle size greater than 1 μm and less than 45 μm and/or aggregates of the silicon fine particles and comprises silicon ox...  
WO/2023/189402A1
[Problem] The purpose of the present invention is to further develop the invention of useful agents having 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient, which the present inventor has already acquired, and to provide use...  
WO/2023/184828A1
Provided are a chitosan oligosaccharide nano microsphere and a preparation method therefor. The method comprises: preparing a sodium alginate aqueous solution, a chitosan oligosaccharide aqueous solution and a calcium chloride aqueous so...  
WO/2023/190117A1
The present disclosure addresses the problem of providing a method for producing a new ellagic acid-containing composition capable of improving solubility of ellagic acid. The present embodiment is a method for producing an ellagic acid-...  
WO/2023/178840A1
A pharmaceutical composition for improving the life quality of elderly people on the basis of vitamin K2, the pharmaceutical composition being composed of composition I and composition II, the mass ratio of which is (0.5-7):1. Also provi...  
WO/2023/178445A1
Disclosed herein are iron-chelating polymers for treatment of diseases with an iron-mediated pathology, said polymers comprising a reaction product of a first monomer unit and a second monomer units polymerized by a reversible addition-f...  
WO/2023/178799A1
A pharmaceutical composition containing vitamin K2 for improving cardiovascular calcification. The pharmaceutical composition is composed of composition I, composition II, and composition III, the mass ratio of which is (0.1-5):(0.01-0.5...  
WO/2023/181755A1
Provided is: a highly-safe and low-cost expression regulator for a factor particularly involved in maturation, moisture retention, or barrier function of the skin; an expression enhancer for an antimicrobial peptide; an expression enhanc...  
WO/2023/183543A1
Disclosed is a method for forming selenoneine or analogs thereof. The method may include phosphorylating sodium selenide to a selenophosphate, using adenosine triphosphate (ATP) and at least a first protein, generating a selenosugar by c...  
WO/2023/176871A1
The present description discloses a means that enables the prevention of the decrease in the amount of reduced coenzyme Q10 due to oxidization during the storage of a solid composition containing the reduced coenzyme Q10. One or more e...  
WO/2023/176875A1
The present description discloses a means for suppressing a decrease, through oxidation, of the reduced coenzyme Q10 when a solid composition containing the reduced coenzyme Q10 is preserved. One or more embodiments of the present inve...  
WO/2023/176878A1
The present description discloses a means that is capable of suppressing a reduced coenzyme Q10 from decreasing due to oxidation when a solid composition containing the reduced coenzyme Q10 is preserved. One or more embodiments of the ...  
WO/2023/170229A1
The invention relates to 1) an aronia extract comprising proanthocyanidins (PACs) and anthocyanins, wherein the polyphenol content is at least 55 dry wt.%, the PACs content is at least 19 dry wt.%, and the PACs:anthocyanins ratio is at l...  
WO/2023/168771A1
The present invention relates to the field of biotechnology. Provided are an mTOR inhibitor and the use thereof. The mTOR inhibitor is obtained by means of mutating aspartic acids at positions 14, 17 and 18 in 30 amino acids at the C ter...  
WO/2023/169260A1
Provided are a ginseng composition having high utilization of ginsenoside, and a preparation method and an application of the composition. The composition is composed of ginseng powder of 250 meshes or more and β-cyclodextrine, and the ...  
WO/2023/171250A1
The present invention provides a production system and a production method for a flavan oligomer, the system and method being capable of efficiently synthesizing, at high yield, a flavan oligomer in which flavan derivatives are bonded to...  
WO/2023/160405A1
Provided is a compound NMNH disodium salt, and the present invention in particular relates to a polymorph of a reduced β-nicotinamide mononucleotide disodium salt, and a preparation method therefor and the use thereof as a pharmaceutica...  

Matches 51 - 100 out of 10,388